Dexcom stock forecast 2027–2029
MyStockButler's October 2026 analysis: Dexcom's weighted value is $87.72 in October 2029, with a 30% bear, 55% base and 15% bull case. It hinges on whether Dexcom can make broader access produce durable users, better margins and real cash per share.
Where could Dexcom's shares be by 2029?
The forecast points to a weak near term and only modest three-year upside. In October 2027, weighted value is $75.70, a 12% loss with dividends. In October 2028 it is $81.06, a 6% loss. By October 2029 it reaches $87.72, a 2% gain.
The final-date range runs from bear $52.17 to bull $148.46. Today's price is $85.98. The weighted result assigns 30% to the bear case. The base case receives 55%. The bull case receives 15%.
| Case | Probability | October 2027 | October 2028 | October 2029 |
|---|---|---|---|---|
| Bear | 30 % | 59.62 (-31 %) | 54.88 (-36 %) | 52.17 (-39 %) |
| Base | 55 % | 79.21 (-8 %) | 84.96 (-1 %) | 90.54 (+5 %) |
| Bull | 15 % | 94.99 (+10 %) | 119.12 (+39 %) | 148.46 (+73 %) |
| Weighted | 100 % | 75.70 (-12 %) | 81.06 (-6 %) | 87.72 (+2 %) |
What has to go right for Dexcom, and what could go wrong?
That path is supported by first-half 2026 net margin of about 18.0% and management's target of at least 10% organic annual growth through 2030. It also assumes gradual benefits from coverage, repeat orders and manufacturing efficiency. The bear case produces earnings of $896 million, $940 million and $987 million because revenue grows only 5% annually and margin stays at 16.5%. The bull case reaches $1,110 million, $1,325 million and $1,572 million because growth starts at 15%, then remains 13%, while margins expand from 19.0% to 21.0%.
The bull case assumes broader type 2 adoption, stronger repeat use, reliable Ireland output and better manufacturing economics. The price reaches $94.99 in October 2027 and $148.46 in October 2029. Its 15% probability reflects the need for several execution-dependent gains to occur together, while current quality costs remain unresolved.
How much cash does Dexcom really make?
Revenue growth recovered to 15.6% in 2025, while operating margin reached 19.6%. Real free cash flow computed from the cash-flow statement reached 19.7% of sales, but the key economic test remains the company’s $2.26 of real free cash flow per share after stock-based pay.
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash from operations | 1,440.7 | 989.5 | 748.5 | 669.5 | 442.5 |
| − Capital spending | 363.5 | 358.8 | 236.6 | 364.8 | 389.2 |
| = Free cash flow | 1,077.2 | 630.7 | 511.9 | 304.7 | 53.3 |
| − Stock pay | 159.6 | 170.4 | 150.8 | 126.5 | 113.4 |
| = Real free cash flow | 917.6 | 460.3 | 361.1 | 178.2 | -60.1 |
What this means. The company's own free cash flow matches ours; the tiny 2022 difference is just rounding, and it did not publish its own figure for 2021.
What does Dexcom's share price pay for in earnings and cash?
| Today (Oct 20, 2026) | |
|---|---|
| Share price | 85.98 |
| P/E, last 12 months (calculated) | 34.0x |
| P/E, next 12 months (calculated) | 27.5x |
| Free cash flow yield (calculated) | 3.3% |
| Real free cash flow yield (calculated) | 2.8% |